Fig. 7

Comparison of OS in ESCC patients with no history of radical surgery (C: Chemotherapy group, CC: Chemotherapy plus camrelizumab group)
Comparison of OS in ESCC patients with no history of radical surgery (C: Chemotherapy group, CC: Chemotherapy plus camrelizumab group)